In two years, biopharmaceutical companies have gone from zero to 13 billion COVID-19 
vaccine doses produced. They’ve worked across the industry and on every continent to meet 
the global demand for COVID-19 innovation. Yet global trade officials will gather for the 
World Trade Organization (WTO) ministerial meeting in June to debate whether and how to al
low countries to confiscate intellectual property (IP) rights for pandemic-related products 
as part of the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. 
Here are three reasons that underscore why it’s unthinkable to focus on IP waivers, and whe
re policymakers should concentrate efforts instead
